ArticleChemical biology & drug design2026
Benzothiazepane-Based Curcumin Analogs Show Selective Effects on Respiration, Permeability, and Growth of Gut-Liver (Co-Culture) Cell Models.
Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Curcumin, a natural polyphenol with anti-cancer potential, faces limitations due to metabolic instability, and non-specific toxicity. This study focused on four curcumin analogs (FM038, FM044, FM045, FM050) featuring oxobutenylidene-substituted benzothiazepane cores bearing pyridinyl or furan substituents. We systematically evaluated their selective toxic effect on human colon (Caco-2) and liver (HepG2) cells. This study reveals that structural modifications critically govern the selective cytotoxicity of curcumin analogs towards proliferating Caco-2 and HepG2 cells. Treatment with analogs featuring pyridin-2-yl substituents (FM045/FM050) resulted in a slightly reduced potency towards Caco-2 cells compared to curcumin, whereas FM044 (furan-2-yl) was non-toxic and FM038 (pyridin-3-yl, methylated core) maintained similar activity. In contrast, direct exposure to proliferating HepG2 cells resulted in less cytotoxicity compared to the Caco-2 cell line, which points to a cell-specific mode-of-action in growing cells. When combined in a co-culture, metabolites generated and/or transported by differentiated Caco-2 cells significantly decreased HepG2 viability at an apical concentration of 15 μM. Efflux analysis of respiration and acidification showed that FM050 induced the strongest mitochondrial dysfunction in Caco-2 cells, directly driving cytotoxicity, whereas HepG2 toxicity correlated with intrinsic detoxification capacity rather than mitochondrial disruption. A metabolic shift towards glycolysis was observed in both cell lines, indicating energy pathway modulation to a more dysfunctional phenotype. These findings highlight the dual role of structural optimization (e.g., methylation, heterocyclic substituents) for (cancer) cell-specific bioactivity and colonic metabolism and may guide future development of curcumin-based chemopreventive agents after in vivo validation and metabolite characterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.